Shares of Lantheus Holdings Inc (NASDAQ:LNTH) have been given a consensus rating of “Hold” by the seven analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $24.00.
Several research analysts have weighed in on LNTH shares. Jefferies Group raised their price objective on shares of Lantheus from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Wells Fargo & Company raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 price objective for the company in a report on Tuesday, November 7th. Credit Suisse Group raised their price objective on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Finally, ValuEngine lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, December 1st.
In other news, insider Michael P. Duffy sold 11,917 shares of Lantheus stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $21.63, for a total value of $257,764.71. Following the completion of the transaction, the insider now directly owns 152,301 shares of the company’s stock, valued at approximately $3,294,270.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO John W. Crowley sold 6,755 shares of Lantheus stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,986 shares of company stock valued at $625,488. 2.30% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. Marshall Wace North America L.P. boosted its holdings in shares of Lantheus by 1,214.5% in the 2nd quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock valued at $18,975,000 after buying an additional 973,977 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Lantheus by 87.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock valued at $26,093,000 after buying an additional 689,954 shares during the period. State Street Corp boosted its holdings in shares of Lantheus by 3,932.8% in the 2nd quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after buying an additional 601,714 shares during the period. Peregrine Capital Management LLC acquired a new position in shares of Lantheus in the 3rd quarter valued at about $8,062,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Lantheus in the 2nd quarter valued at about $7,396,000. 91.91% of the stock is owned by institutional investors and hedge funds.
Shares of Lantheus (NASDAQ LNTH) opened at $20.15 on Wednesday. Lantheus has a one year low of $7.95 and a one year high of $24.10. The stock has a market cap of $738.87, a price-to-earnings ratio of 17.59, a P/E/G ratio of 1.56 and a beta of 0.94. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.04. The firm had revenue of $79.94 million for the quarter, compared to the consensus estimate of $77.18 million. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.15 EPS. analysts expect that Lantheus will post 1.05 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/lantheus-holdings-inc-lnth-receives-average-recommendation-of-hold-from-analysts.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.